title: What will be the role of I-123 MIBG in improving the outcome of medically treated heart failure patients?
authors.affiliation: Division of Cardiovascular Diseases, Department of Internal Medicine, University of Cincinnati College of Medicine, P.O. Box 670542, Cincinnati, OH 45267-0542, USA.
authors.forename: Fahad
authors.initials: F
authors.lastname: Waqar
authors.forename: Stephanie H
authors.initials: SH
authors.lastname: Dunlap
authors.forename: Myron C
authors.initials: MC
authors.lastname: Gerson
mesh_terms: D019797:3-Iodobenzylguanidine; D057911:Angiotensin Receptor Antagonists / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006333:Heart Failure / Q000000981:diagnostic imaging* / Q000188:drug therapy*; D006801:Humans; D015201:Meta-Analysis as Topic; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use; D019275:Radiopharmaceuticals; D016032:Randomized Controlled Trials as Topic; D015899:Tomography, Emission-Computed, Single-Photon / Q000379:methods*; D016896:Treatment Outcome
chemical_list: D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000451:Mineralocorticoid Receptor Antagonists; D019275:Radiopharmaceuticals; D019797:3-Iodobenzylguanidine